Adaptive Clinical Trials: Overview of Phase III Designs and Challenges

Adaptive designs use accruing data to make changes in an ongoing trial according to a prespecified plan and potentially offer great efficiencies for clinical development. There are many types of adaptive designs and many trial aspects that could in theory be adapted. However, the scope of adaptive designs with relevance in confirmatory trials is narrower, and in addition, extensive pre-planning is needed and various types of challenges need to be addressed in order to use these designs in this stage of development. Nevertheless, with careful planning, there are opportunities for these designs to offer important benefits even in the confirmatory stage of development. We provide an overview of adaptive designs that have relevance for confirmatory trials and discuss considerations that may affect whether they should or should not be used in particular trials or programs as well as the challenges that need to be addressed.

[1]  M A Proschan,et al.  Designed extension of studies based on conditional power. , 1995, Biometrics.

[2]  Frank Bretz,et al.  Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.

[3]  Cyrus R Mehta,et al.  Adaptive increase in sample size when interim results are promising: A practical guide with examples , 2011, Statistics in medicine.

[4]  M Kieser,et al.  Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.

[5]  Sue-Jane Wang,et al.  Modification of Sample Size in Group Sequential Clinical Trials , 1999, Biometrics.

[6]  P. Bauer,et al.  Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.

[7]  Gernot Wassmer,et al.  Designing Issues in Confirmatory Adaptive Population Enrichment Trials , 2015, Journal of Biopharmaceutical Statistics.

[8]  Pascale Tubert-Bitter,et al.  Targeting population entering phase III trials: A new stratified adaptive phase II design , 2011, Statistics in medicine.

[9]  T. Friede,et al.  A conditional error function approach for subgroup selection in adaptive clinical trials , 2012, Statistics in medicine.

[10]  Mark C. K. Yang,et al.  Interval estimation for drop-the-losers designs , 2010 .

[11]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[12]  P. Gallo.  Confidentiality and Trial Integrity Issues for Adaptive Designs , 2006 .

[13]  C. Tournoux-Facon,et al.  How a new stratified adaptive phase II design could improve targeting population , 2011, Statistics in medicine.

[14]  Christopher Jennison,et al.  Mid‐course sample size modification in clinical trials based on the observed treatment effect , 2002, Statistics in medicine.

[15]  Jack Bowden,et al.  Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials , 2008, Biometrical journal. Biometrische Zeitschrift.

[16]  Donald A. Berry,et al.  Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development , 2009 .

[17]  Sue-Jane Wang,et al.  Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset , 2007, Pharmaceutical statistics.

[18]  R. Simon,et al.  On the efficiency of targeted clinical trials , 2005, Statistics in medicine.

[19]  R. Temple,et al.  Enrichment designs: efficiency in development of cancer treatments. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Frank Bretz,et al.  Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts , 2006, Biometrical journal. Biometrische Zeitschrift.

[21]  S. Pocock.  Group sequential methods in the design and analysis of clinical trials , 1977 .

[22]  Meinhard Kieser,et al.  Simple procedures for blinded sample size adjustment that do not affect the type I error rate , 2003, Statistics in medicine.

[23]  W. Lehmacher,et al.  Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.

[24]  C. Mehta,et al.  Population Enrichment Designs: Case Study of a Large Multinational Trial , 2011, Journal of biopharmaceutical statistics.

[25]  Gernot Wassmer,et al.  On Sample Size Determination in Multi-Armed Confirmatory Adaptive Designs , 2011, Journal of biopharmaceutical statistics.

[26]  Werner Brannath,et al.  Shrinkage estimation in two‐stage adaptive designs with midtrial treatment selection , 2013, Statistics in medicine.

[27]  Frank Bretz,et al.  TUTORIAL IN BIOSTATISTICS Adaptive designs for confirmatory clinical trials , 2022 .

[28]  Vladimir Dragalin,et al.  Likelihood inference for a two‐stage design with treatment selection , 2010, Biometrical journal. Biometrische Zeitschrift.

[29]  H. Magnussen,et al.  Integrating Indacaterol Dose Selection in a Clinical Study in COPD Using an Adaptive Seamless Design. , 2009, ATS 2009.

[30]  Jeff Maca,et al.  Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples , 2006 .

[31]  A. Tsiatis,et al.  On the inefficiency of the adaptive design for monitoring clinical trials , 2003 .

[32]  D. DeMets,et al.  Increasing the sample size when the unblinded interim result is promising , 2004, Statistics in medicine.

[33]  Richard Simon,et al.  Evaluation of randomized discontinuation design. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Simon,et al.  An agenda for Clinical Trials: clinical trials in the genomic era , 2004, Clinical trials.

[35]  Martin Posch,et al.  Testing and estimation in flexible group sequential designs with adaptive treatment selection , 2005, Statistics in medicine.

[36]  C. Jennison,et al.  An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.

[37]  Sue-Jane Wang,et al.  Adaptive patient enrichment designs in therapeutic trials , 2009, Biometrical journal. Biometrische Zeitschrift.

[38]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[39]  Cyrus Mehta,et al.  Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies , 2009, Circulation.